美国慢性乙肝成人一次性普遍HDV检测的成本效果
该研究用Markov模型评估美国HBsAg阳性成人一次性普遍HDV抗体检测(阳性者再测HDV RNA)的成本效果。每10万筛查者中,普遍检测可避免100例HDV相关死亡、30例肝硬化和50例肝细胞癌,并增加1500个QALY。在5万美元/QALY支付阈值下,普遍检测联合PEG-IFN治疗可能具有成本效果。
要点
- 美国仅约12.9%的CHB成人接受过HDV抗体检测。
- 每10万HBsAg阳性者筛查,普遍检测可避免100例HDV相关死亡。
- 在5万美元/QALY阈值下,普遍检测联合PEG-IFN治疗可能具有成本效果。
核心结论
- 对美国所有HBsAg阳性成人进行一次性HDV检测,并对慢性HDV感染使用PEG-IFN治疗,可能具有成本效果。
研究设计与样本
- 采用Markov模型计算美国HBsAg阳性成人普遍HDV检测的成本、健康影响和成本效果。
- 假设50%的HDV RNA阳性患者接受当前推荐的PEG-IFN治疗48周,应答率为30%。
- 还模拟了假设性无限期HDV抗病毒治疗(更高应答率)的影响,以评估具有成本效果的年度药物成本阈值。
主要发现
- 每10万HBsAg阳性个体筛查,普遍HDV检测可避免100例HDV相关死亡、额外30例肝硬化和50例肝细胞癌。
- 每10万HBsAg阳性个体筛查,普遍HDV检测可能带来1500个质量调整生命年(QALY)的增益。
临床怎么用
- 研究结果支持对美国HBsAg阳性成人考虑一次性普遍HDV检测,并对慢性HDV感染使用PEG-IFN治疗,因其可能具有成本效果。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis D virus (HDV) infection increases the risk of liver-related deaths in adults with chronic hepatitis B (CHB). In the United States (US), only an estimated 12.9% of adults with CHB have received an HDV antibody test. The aim of this study is to calculate the cost-effectiveness of one-time universal HDV testing of hepatitis B surface antigen (HBsAg)-positive adults living in the US. METHODS: A Markov model was used to calculate the costs, health impact, and cost-effectiveness of universal testing of HBsAg-positive adults with an HDV antibody test and, when positive, an HDV RNA test for chronic HDV infection. We assumed that 50% of the HDV RNA-positive patients would receive the current recommended treatment with pegylated interferon (PEG-IFN) for 48 weeks with a 30% response rate. We also modeled the potential impact of hypothetical indefinite HDV antiviral therapy with a higher response rate to assess the annual cost threshold to be considered cost-effective. RESULTS: Universal HDV testing of adults with CHB could avert 100 HDV-related deaths and an additional 30 cases of cirrhosis and 50 cases of hepatocellular carcinoma, and potentially result in a gain of 1500 quality-adjusted life-years (QALYs) per 100 000 HBsAg-positive individuals screened. At a willingness-to-pay threshold of $50 000 per QALY, the annual drug costs for a hypothetical indefinite therapy with a 50% or 70% treatment response rate would need to cost ≤$13 027 and ≤$14 104, respectively. CONCLUSIONS: One-time HDV testing for all HBsAg-positive adults and treatment of chronic HDV infection with PEG-IFN is potentially cost-effective in the US.
引用
- Toy M, Hutton D, Teshale E, et al. Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States. Clin Infect Dis. 2025. PMID: 40198094. doi:10.1093/cid/ciaf181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。